Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

How to measure and evaluate binding affinities

Inga Jarmoskaite, Ishraq AlSadhan, Pavanapuresan P Vaidyanathan and 1 more

eLife · 2020 · CC BY

doi:10.7554/elife.57264

Abstract

Quantitative measurements of biomolecule associations are central to biological understanding and are needed to build and test predictive and mechanistic models. Given the advances in high-throughput technologies and the projected increase in the availability of binding data, we found it especially timely to evaluate the current standards for performing and reporting binding measurements. A review of 100 studies revealed that in most cases essential controls for establishing the appropriate incubation time and concentration regime were not documented, making it impossible to determine measurement reliability. Moreover, several reported affinities could be concluded to be incorrect, thereby impacting biological interpretations. Given these challenges, we provide a framework for a broad range of researchers to evaluate, teach about, perform, and clearly document high-quality equilibrium binding measurements. We apply this framework and explain underlying fundamental concepts through experimental examples with the RNA-binding protein Puf4.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Molecular associations lie at the heart of biology. Their thermodynamics provides information critical for deriving a fundamental understanding of molecular functions. In a broader biological context, these associations are linked and interconnected in complex networks that allow sensitive and precise developmental programs and responses to environmental cues, and that are altered in disease states. The outputs of pathways and networks are determined by the quantitative interplay of their many constituent molecules and interactions. Thus, equilibrium constants for association between network components are needed to define, model, predict, and ultimately precisely manipulate biology.

A limitation of traditional biochemical measurements is their low throughput, especially in relation to the large number of cellular interactions. Excitingly, several strategies have recently emerged to obtain high-throughput, quantitative information for intermolecular associations (e.g.;;;;;; ). Given these potentially transformative advances, it is especially timely to assess the accuracy of equilibrium binding measurements. We wanted to know whether current practices are sufficient to ensure reliable and accurate measurements, and whether the reliability of these measurements can be readily ascertained from the information provided in published work.

Our survey of 100 literature binding measurements, presented below, uncovered recurring problems with a large majority of studies. Fortunately, there are straightforward procedures, laid out here, that can be followed to ensure that published binding measurements are reliable. The principles underlying these procedures have been discussed and we build on these previous reports. We focus on a minimal set of critical actionable steps and controls that biologists of any background should be able to implement in their binding measurements. We apply these procedures with experimental examples and also demonstrate the pitfalls of omitting essential controls. To further streamline application of these standard procedures, we provide a convenient checklist that can organize and guide experiments and can be used as an aid in summarizing and presenting results for publication.

Assessing the current state of binding measurements

We evaluated published binding measurements using RNA-protein interactions as an illustrative example. We surveyed 100 studies that reported equilibrium dissociation constants (KD values) and scored them based on two key criteria for reliable binding measurements: sufficient time to equilibration and proper concentration regime (Figure 1).

First, we asked if equilibration was demonstrated. By definition, an equilibrium state is invariant with time. So, determining a binding equilibrium constant requires showing that there is no change in the amount of bound complex over time. Of the 100 studies surveyed, 70 did not report varying time for reported equilibrium measurements (Figure 1; Supplementary file 1). Of the 30 studies that did vary time, 24 exclusively used techniques with built-in monitoring of progress over time (isothermal titration calorimetry (ITC) and surface plasmon resonance [SPR]). Of the remaining 76 studies—those using approaches such as native gel shifts, nitrocellulose filter binding, and fluorescence anisotropy—less than 10% reported varying time (Figure 1, Figure 1—figure supplement 1).

We know from individual discussions that some researchers carry out these controls, as we advocate below, but do not report them. Unfortunately, the published record then cannot distinguish between these studies and others that have not demonstrated equilibration.

A second critical control entails demonstrating that the KD is not affected by titration, as artifacts can arise when the concentration of the constant limiting component is too high relative to the dissociation constant (KD). Similar to varying time to establish equilibration, systematically varying the concentration of the limiting component provides a definitive control for effects of titration. In our survey, only 5% of studies reported performing this or equivalent control (Figure 1—figure supplement 2). Nevertheless, most authors appeared to be aware of the need to avoid titration, as the majority of studies (~70%) reported using appropriately low concentrations of the limiting component or employed advanced analysis methods. We consider these examples as reasonably titration-controlled for the purpose of the survey, but emphasize the importance of empirical controls in the sections below. Importantly, this leaves, at a minimum, one-fourth of studies at risk for titration (Figure 1, Figure 1—figure supplement 2).

To what extent do these limitations affect the reported equilibrium binding constants in practice? As an example, for Puf4 binding (see below), not controlling for the factors above gave apparent KD values that were up to seven-fold higher than the actual KD values. A more extreme literature example is discussed in the next section, with discrepancies reaching 1000-fold, and other examples have been previously noted. There is a tendency to be less careful about controls in pursuit of relative affinities (specificity) rather than absolute affinity. However, failing to account for the factors noted above can also underestimate specificity by orders of magnitude (see Figure 4—figure supplement 1 and Figure 5—figure supplement 4 below).

These observations highlight an urgent need to revisit the criteria for reliable binding measurements. There is a parallel need to render these criteria accessible to a broad range of biologists, regardless of background or training, in the form of clear and readily actionable guidelines. To meet these needs, we provide simple, concrete strategies so that any practitioner can carry out reliable binding measurements, clearly communicate their results, and evaluate results from others.

Fortunately, the key requirements for binding measurements can be broken down into a small number of steps. We present two required steps for equilibrium binding measurements—varying the incubation time (see section 'Vary incubation time to test for equilibration') and controlling for titration (see section 'Avoid the titration regime'), and we illustrate these steps for the example of RNA binding to the Saccharomyces cerevisiae Puf4 protein. We also present additional steps that can be taken to further increase confidence in KD values and to obtain kinetic information about the binding event under investigation (see sections 'Test KD by an independent approach' and 'Determine the fraction of active protein'). Finally, we describe strategies to address cases where no binding is initially detected and explain why it is often premature to conclude an absence of binding (see section 'The case of no observed binding').

Practical considerations

In principle, one would like to have well-behaved and perfectly controlled measurements in all cases, but biology and biochemistry can be messy. There are many times, working with extracts and partially purified systems where protein concentrations cannot be accurately determined, where proteases and nucleases may limit achievable equilibration times, and where there may be additional interacting components. Regardless of these potential complications, the simple steps indicated below can establish the robustness of measured affinities and can diagnose and help overcome issues like loss of activity over time. Moreover, these controls (and quantitative measurements more generally) can help uncover new features and regulatory mechanisms, based on deviations from ‘ideal’ behavior of simple binding equilibria.

Vary incubation time to test for equilibration

The most basic test for whether a binding reaction has reached equilibrium is that the fraction of complex formed between two molecules does not change over time. Nevertheless, the majority of papers we surveyed that present binding measurements and report apparent affinities or equilibrium dissociation constants do not report that time has been varied (Figure 1). We first describe two related concepts that will help readers develop an intuition for the time scales of binding processes and we then apply these concepts to Puf4 binding.

Half-life

Binding and other simple kinetic processes, in general, follow exponential curves (Figure 2). The key property of an exponential curve is that it has a constant half-life (t1/2)—that is, the time it takes for the reaction to proceed from 0% to 50% complete, 50% to 75% complete, 75% to 87.5% complete, etc. is the same (Figure 2). After three half-lives, an exponential process is almost 90% complete (3t1/2 = 87.5%; Figure 2), which is close enough to equilibration for most applications. Below we adopt the more common standard of taking reactions to five half-lives, or 96.6% completion; this more conservative standard is safer given that there are multiple sources of potential error in practice.

Equilibration rate constant

The equilibration rate constant is effectively the inverse of the binding half-life (kequil = ≈ ) and, importantly, is concentration-dependent. For the binding equilibrium shown in Figure 3, under conditions where one binding partner (here, the protein, P) is in large excess over the other (RNA), the rate equation for approach to equilibrium, kequil, is described as: kon is the association rate constant, [P] is the concentration of protein, or the binding partner in excess, and koff is the dissociation rate constant. According to Equation 1, equilibration is the slowest at the lowest protein concentrations. For this reason, equilibration times need to be established from the low end of the concentration range. In practice, it is useful to consider the limiting case with the protein concentration approaching zero ([P] ~ 0), such that Equation 1 simplifies to Equation 2:

Thus, the more long-lived the complex (i.e. the lower its dissociation rate constant), the longer the incubation time required to reach equilibrium.

What is the range of equilibration times for typical biomolecular interactions? While koff measurements (and, consequently, kequil) are less common in literature than KD measurements, equilibration times can be readily estimated. Given that KD = (Figure 3) and assuming that the binding of molecules occurs as fast as diffusional collisions (kon = 108 M−1s−1), we can calculate that an interaction with a KD value of 1 pM would require a 10 hr incubation to reach equilibrium, whereas a 1 µM KD interaction would only require 40 ms (Table 1). Notably, binding rate constants for processes involving macromolecules are often smaller than the diffusion driven limit of ~108 M−1s−1, for example when additional conformational rearrangements are required for stabilizing binding after two molecules collide. As a result, equilibration can take much longer. Thus, equilibration times for two interactions with the same KD value can vary by orders magnitude, and some reactions in the biologically relevant affinity range can require equilibration times of 10s of hr or even longer in vitro (Table 1;; ). These long times underscore that biology has developed mechanisms to circumvent or utilize such slow processes—for example, rapid association may be facilitated by high intracellular concentrations of binding partners, and cellular factors such as molecular chaperones, helicases, chromatin remodelers, or translation can speed up binding and dissociation.

Implications of insufficient equilibration

Despite the realistic possibility of long equilibration times for biological association events, nearly 90% of the reported incubation times were 1 hr or less (Figure 1—figure supplement 1B). As a concrete example, several ‘equilibrium’ dissociation constants reported for CRISPR nucleases, which are well known for tight RNA and/or DNA binding, were determined from incubations of 1 hr or less (e.g.;;;;;;;;;;;; Supplementary file 2). But when target dissociation of these proteins was measured over time, it took many hours, suggesting that equilibration takes much longer than an hour and that the reported KD values based on these short incubation times underestimate the true binding strength. In one striking example, kinetic measurements revealed an equilibration time of >100 hr for the Cas12a complex and an equilibrium constant that was 1000-fold lower than previously reported for the same enzyme at similar conditions after much shorter incubation time. Insufficient incubation times for tight binders may have also led to underestimation of specificity, a topic of central concern for CRISPR targeting (and for much of biology). Figure 4—figure supplement 1 illustrates how target affinities that differ by two orders of magnitude may appear identical if the incubation time is too short.

An example in which extending the incubation time changed the mechanistic interpretation comes from studies of the signal recognition particle (SRP). Originally, the observation that 4.5S RNA enhanced the assembly of the signal recognition particle (SRP) and SRP receptor led to a proposed mechanism in which the 4.5S RNA stabilized the complex. Subsequently, binding studies extended to longer times revealed that the 4.5S RNA accelerated the otherwise slow SRP/receptor binding and dissociation without affecting the binding affinity. Exploring the time dependence of the assembly process changed the mechanistic conclusions: 4.5S RNA could be shown to play a catalytic, rather than stabilizing role in SRP/receptor assembly.

Figure 4—figure supplement 1 illustrates how incubation times that are very far from equilibrium can lead to systematic deviations of the data from the fit to an equilibrium binding equation. While a poor fit is not sufficient to diagnose insufficient equilibration (and, conversely, a good fit does not prove complete equilibration), an inability to fit the data well to a simple binding model provides an important indicator that additional controls are required. Only after simple controls for equilibration and titration (see below) have been performed, should more complex binding models, such as cooperativity, be considered, unless such models are independently supported. Indeed, among the studies in our literature survey omitting one or both key controls, several included poorly fit binding curves. Importantly, graphs of fits of the data to a clearly defined equilibrium binding model should be published along with the KD values when possible, and the quality of the fit over the entire concentration range should always be carefully assessed. In summary, the incubation time must be varied to ensure equilibration, ideally across a range of at least 10-fold. Below we illustrate this control, and the need for it, with experimental results for Puf4 binding to its consensus RNA.

Time dependence of Puf4 binding at 25°C and 0°C

To establish the equilibration time for Puf4 binding to its cognate RNA sequence, Puf4 was mixed, over a series of concentrations, with a trace amount of labeled RNA (in this case, 32P-labeled; 0.002–0.016 nM) and incubated for a specified time (t1) (Figure 4A). The fraction of bound RNA was subsequently determined by non-denaturing gel electrophoresis (see Materials and methods).

At 25°C, we observed the same amount of binding with incubations of t1 = 30 min, 1.5 hr, and 4.5 hr at each protein concentration, providing strong evidence for equilibration even at the shortest time (Figure 4B). Consequently, we can proceed to the next key control at this condition, using an incubation time of ≥30 min.

We also present Puf4 binding results at 0°C as these data provide an example of slow equilibration and because many binding studies report incubations on ice to stabilize binding. Indeed, the results at 0°C were very different than those at 25°C. As shown in Figure 4C, Puf4 bound different amounts of RNA in the 30 min, 1.5 hr, and longer incubations. Not until the incubation was extended to 4.5 hr did the extent of binding level off at the lowest Puf4 concentrations—that is, the amount bound was the same after 4.5 and 24 hr. Consequently, equilibration of Puf4–RNA binding on ice requires at least 4.5 hr, and incubation for only 30 min would give an apparent KD value that is seven times higher than after a 24 hr incubation. Moreover, binding at 0°C was so tight that we were only able to obtain part of the binding curve while maintaining the protein concentrations in excess of labeled RNA (Figure 4C). The importance of this excess to obtain reliable KD values is described in the next section. In the 0°C case and more generally, it is important to re-assess the equilibration time after establishing that binding is in an appropriate concentration regime, as we demonstrate in later sections. Similarly, changes in conditions, such as salt concentration, temperature or pH, can affect both the affinity and the equilibration time and therefore should be accompanied by confirming that equilibration has occurred.

Avoid the titration regime

The most common approach to measuring affinity is to vary the concentration of one component, while keeping the concentration of the other binding partner constant. However, this experimental design is not always sufficient, as there are two limiting regimes, determined by the concentration of the constant component; only one of these concentration regimes allows the KD to be reliably determined, while the other does not.

In the first, ‘binding’ regime, the concentration of the constant (‘trace’) component, R, is well below the dissociation constant ([R]total << KD for the example in Figure 3). In this case, the concentration of the variable component (P in Figure 3) that gives half binding is equal to the KD (Figure 5A). In the other, ‘titration’ regime, the concentration of the constant component is much greater than the KD ([R]total >> KD) so that essentially all added P is depleted from solution due to binding to R, until there is no more free R left to bind. In this case, the concentration of P that gives half binding does not equal or even approximate the KD. Rather, at high excess of R over the KD, the concentration of P that gives half binding is simply half of the concentration of (active) R molecules—a value that can differ from the sought-after KD by orders of magnitude (Figure 5B; Figure 5—figure supplement 1).

A potentially useful intermediate regime exists between the two extremes, with limiting component concentrations similar to or in modest excess over the KD. The KD can be determined in this regime by using an appropriate binding equation, although with potential pitfalls (see below).

Distinguishing between concentration regimes

The challenge is that distinguishing between the regimes requires the knowledge of the KD, and consequently it is impossible to know a priori which regime holds. A useful rule of thumb for avoiding the titration regime is to always maintain the concentration of the excess binding partner significantly above that of the trace limiting partner. The reason for this can be gleaned from the equation that describes the fraction of bound RNA for the simple binding scheme of Figure 3:

Here [P]free is the unbound protein concentration and KD is simply the free protein concentration at which half of the RNA is bound. But while Equation 4a holds universally, in practice we only know the total concentration of P, [P]total—how much we added to the solution—not the free concentration ([P]free). Therefore, we want to operate under simplifying conditions where [P]free ≈ [P]total so that we can substitute [P]total into Equation 4a to give Equation 4b:

The condition [P]free ≈ [P]total holds true if P is in large excess of RNA across the entire experiment, meaning that only a small fraction of total protein is used up by binding to RNA. Most importantly, this condition must hold for the protein concentration that gives half-saturation to determine the KD; hence the requirement for the binding regime that the concentration of the limiting component must be <<KD. Nevertheless, simply maintaining an excess of protein over the limiting component may not always be sufficient to maintain a binding regime, given the uncertainty often surrounding concentration measurements and even greater uncertainty surrounding active concentrations.

In principle, a more complex quadratic binding equation provides an alternative to working under the [P]free ≈ [P]total assumption, as it explicitly accounts for bound protein:

Indeed, several techniques (most notably ITC) commonly operate outside the binding regime and rely on Equation 5 (or equivalent formulations) for data fitting. Importantly, the quadratic equation is only applicable to the intermediate and binding regimes, but not the titration regime. The reason for this is that at very high concentrations relative to the KD, the contribution of KD in determining the fraction bound (Equation 5) becomes negligible, and as a result a meaningful KD value cannot be extracted from the fit to the binding data. Simulated data in Figure 5—figure supplements 2 and 3 illustrate this limitation. Consequently, even when using Equation 5, the concentration of the limiting component should be kept to a minimum to avoid the titration regime.

Where does the intermediate regime end and titration begin? The answer depends on the technique and the quality of the data. For ITC measurements, which provide highly precise information for each added binding aliquot, up to 1000-fold excess of the limiting species over the measured KD can be acceptable. However, in most other cases, this limit is much lower. Simulations in Figure 5—figure supplement 3 suggest that up to ~10-fold excess consistently allows for reasonably well-defined KD values in the presence of typical binding data, and up to 100-fold excess can be useful for data with minimal noise. In contrast, performing the experiments in the binding regime (fit with Equation 4b) yields well-defined KD values even with substantial noise in the data (Figure 5—figure supplement 3).

Implications of the titration regime

Of the 100 literature studies we surveyed, most (65%) determined KD values under the assumption of the binding regime, by using Equation 4b or equivalent analysis. Nevertheless, the required condition that the limiting species concentration be <<KD was not always supported. One-third of the studies using Equation 4b (n = 21) reported KD values that were comparable to (<10-fold excess) the concentration of the trace component, including nine studies in which the reported KD was indistinguishable from (within ~2-fold) or even below the stated trace component concentration, consistent with an intermediate or even titration regime (Figure 1—figure supplement 2).

The implication in all these cases is that the reported KD values may underestimate the real affinities. Unfortunately, it is difficult to determine the extent of this underestimation post-factum without further experimental controls. To understand why, recall from the example in Figure 5B that in the titration regime the midpoint of the binding curve only reflects ~half the concentration of the limiting species, which sets a lower limit to the apparent KD derived from Equation 4b, even if the real KD is much lower. Conversely, if the midpoint of the binding curve (and the reported KD in the above cases) is approximately the same as the limiting component concentration (allowing for some uncertainty in the concentration), the real KD could be anything below this value, from several-fold to many orders of magnitude less. As with insufficient incubation, systematic deviations of the data from the fit to Equation 4b can be a clear indicator that the apparent KD is limited by titration, but a good fit should not be considered sufficient to prove the binding regime, as experimental uncertainties and other causes can mask deviations.

High-affinity interactions are most susceptible to titration, a corollary of the simple fact that for very low KD values it becomes increasingly difficult to maintain concentrations much lower than KD while still allowing for detection. Since CRISPR nucleases represent some of the most widely studied high-affinity binders, we surveyed a sample of studies to determine the concentration regime under which the reported KD values were measured (Supplementary file 2). Of the 15 studies, the majority (13, or 90%) assumed the binding regime in their analysis, indicated by the use of Equation 4b or equivalent. However, only two of these studies (15%) reported using labeled DNA or RNA concentrations considerably below the apparent KD, and in five cases the lowest reported KD was essentially identical to the labeled RNA or DNA concentration (within ~2-fold), consistent with possible titration.

Importantly, because relative affinities are typically based on the tightest binders, titration effects on the ‘wild-type’ substrate measurements can distort all specificity (relative affinity) values that are based on it. Figure 5—figure supplement 4 illustrates an example, in which two substrates with a 100-fold difference in affinity appear to have identical or near-identical affinities when titration is not controlled for.

Given the impossibility of designing experiments for the binding regime a priori, without knowing the affinity, it is important to rule out titration empirically. Thus, analogously to varying time to establish equilibration, we strongly recommend systematically varying the concentration of the limiting species to establish the binding regime (or, with use of Equation 5, the intermediate regime). The hallmark of a valid KD is that it is not affected by varying the concentration of the limiting component, whereas a titration regime would result in concentration-dependent apparent KD values. At a minimum, this control should always be performed when the measured KD value is comparable to the concentration of the limiting component (Equation 4b), or when Equation 5 yields poorly defined apparent KD values or values much lower than the limiting concentration. Below we demonstrate the titration control for Puf4 affinity measurements.

RNA concentration dependence of Puf4 binding at 25°C and 0°C

We systematically varied the labeled RNA concentration in Puf4 binding experiments at 25°C and 0°C, to illustrate the binding and intermediate regimes, respectively. Figure 5—figure supplement 5 provides a schematic description of the two regimes to help build the reader’s intuition.

At 25°C, the Puf4 binding curves were identical across a nine-fold range of RNA concentrations (Figure 6A,B), and the data were well described by Equation 4b. From the constancy of the binding curves in Figure 6B, we can conclude that the binding regime holds for Puf4 at 25°C, and thus that the observed KD value of 120 pM obtained from Equation 4b represents a true equilibrium constant. As expected for the binding regime, the measured KD is higher than the RNA concentrations (120 pM vs 2–18 pM).

The situation is different at 0°C (Figure 6C). Here, varying the labeled RNA concentration revealed divergent binding curves and a pronounced dependence of apparent affinity (determined by fitting the data to Equation 4b) on the concentration of RNA, the constant component (Figure 6C,D). Moreover, the fits of the data to Equation 4b (solid lines in Figure 6C), which assumes [P]free ≈ [P]total, were poor, increasingly so for higher RNA concentrations. These data are indicative of protein depletion due to binding to labeled RNA. The apparent KD values vary by five-fold across the 30-fold range of RNA concentrations used (Figure 6D, red circles), and even greater discrepancies would arise at higher RNA concentrations (Figure 5—figure supplement 1). Consequently, only an upper limit of the real affinity can be extracted from these data (KD ≤ 2.3 pM, based on the fit value at the lowest RNA concentration used).

To address the limitation in our 0°C data we could, in principle, lower the concentration of labeled RNA even further, until the labeled RNA concentration is <<KD and until an RNA concentration-independent regime is established. But this is difficult when binding is very tight, as a limit is set by the sensitivity of the technique used. In our case, at ~1 pM 32P-labeled RNA we are already near the limit of reliable detection. If the concentration of the trace component cannot be lowered further, a more sensitive approach can sometimes be found. Kinetic approaches are particularly suitable for tight binders (see Appendix 1), or one can report an upper limit of the KD. In some cases, increasing the salt concentration or other changes to the solution or binding partners can be used to weaken binding to make it easier to obtain affinities at higher concentrations of the labeled species; this approach can be especially valuable if one is primarily interested in the relative affinities of multiple ligands.

As noted earlier, the quadratic binding equation enables KD determination for binding reactions in the intermediate regime. The quadratic equation provides a good fit to the 0°C data (Figure 6C, dashed lines) and yields uniform and well-defined KD values of ~1.9 pM across the different RNA concentrations, consistent with an intermediate (rather than titration) regime (Figure 6D, grey circles). The same KD value was obtained from kinetic experiments, providing independent support for and confidence in this determination (Appendix 1).

In summary, we want to use the binding regime whenever possible, as it allows for the most straightforward and reliable KD measurements. It is necessary to avoid the titration regime and caution is required in the intermediate regime. In practice, varying the concentration of both components is an essential control for ruling out titration, ruling out other potential artifacts, and ensuring the measurement of valid dissociation constants.

Re-evaluating the equilibration time at 0°C

In the previous section, we mentioned the need for re-evaluating the equilibration time for Puf4 binding at 0°C after a binding regime was established. In principle, after determining sufficiently low RNA concentration for the binding regime, one could vary the incubation time again, as done in Figure 4. In our case, we used the shortcut defined in Equation 2 and instead determined the upper limit of the equilibration time by measuring the koff at 0°C (Appendix 1; see also Appendix 2—note 1 for precautions when applying this shortcut). These measurements revealed an equilibration time of 30 hr (five half-lives), far above the typical incubation times of 1 hr or less (Figure 1—figure supplement 1).

Dependence of binding affinity on conditions

The 100-fold difference in Puf4 affinity between 0°C and 25°C underscores the important point that the equilibrium dissociation constant is only a constant value at a given set of conditions, and that the affinity can change dramatically when the conditions (temperature, salt, pH) are changed. This dependence on conditions should always be considered when comparing literature values or when applying in vitro results to biology.

Test KD by an independent approach

Even when no challenges are encountered, as in the case of Puf4 binding at 25°C, it is a good idea to determine the KD by a second approach to ensure that the measurement is not biased by experimental artifacts or idiosyncrasies of a particular technique. This is especially important when using a secondary readout (vs. a direct approach) such as native gel shift or nitrocellulose filter binding, where major loss (or gain) of bound complex can potentially occur between the equilibration and detection steps (see below and Appendix 2—note 2).

Of course, there are many approaches to carrying out equilibrium binding measurements one can choose from (e.g.;;; ). Here, we used a kinetic approach for independent KD determination for Puf4 at 25°C and 0°C, as described in Appendix 1. Kinetic measurements provide an information-rich alternative and complement to the equilibrium measurements and are often simple to carry out provided they fall within a measurable time range. In case of Puf4, the affinities determined by kinetic measurements were within two-fold of those from equilibrium determinations, strongly supporting their accuracy.

Determine the fraction of active protein

The amount of bound ligand is determined not by the total protein concentration but by the concentration of total active protein. If 90% of the protein is damaged due to misfolding, aggregation, degradation or, for example, inactivated by phosphorylation at the binding interface, then the observed affinity will be that for only 10% of the total protein present—and will be ten-fold higher than the actual KD value. Moreover, if the binding-competent protein concentration is much lower than the total and therefore much closer to the limiting component concentration than expected, the binding regime may not be maintained, leading to even greater discrepancies between the real and observed KD. As a common cause of non-active or less active protein is aggregation, determining the monodispersity of the protein following purification is advisable.

In addition, we recommend, when possible, a titration experiment to determine the fraction of binding-competent protein. Here, a concentration of ligand that is much greater than the measured KD is intentionally used and the protein concentration is varied by approximately an order of magnitude above and below the ligand concentration. To ensure accurate ligand concentration and to prevent excessive signal (if labeled ligand is used), the trace labeled ligand should be mixed with a large excess of identical unlabeled molecule at a known concentration. Assuming that the stoichiometry of the bound complex is known and that the ligand is 100% active, the breakpoint in fraction bound versus the ratio of protein to ligand indicates the amount of active protein (Figure 7). For example, for a 1:1 complex, a breakpoint at a protein:RNA ratio of 2.0 suggests that half of the protein is active. In Figure 7, the ratio of 1.3 suggests that the Puf4 preparation is 75% active (0.75 = 1/1.3). Consequently, the apparent KD values determined in the previous sections should be multiplied by the active protein fraction (which ranged from 0.75 to 0.90 for Puf4) to determine the final KD value. In an alternative approach, the titration data could be fit to a quadratic equation, with a coefficient used to represent the active protein fraction (Figure 7—figure supplement 1).

A limitation of the titration experiment is that it assumes the constant component to be 100% active, which may not always be the case, especially in the case of protein-protein interactions. Therefore, one should ensure, to the extent possible, maximum purity of both binding components. Importantly, one should always make clear whether experiments were carried out to determine ‘fraction active’.

The case of no observed binding

Researchers often conclude that there is ‘no binding’—that ‘X does not bind to Y’. Typically, the underlying experimental observation is an absence of observed binding up to a certain protein (or ligand) concentration. Therefore, one should report a lower limit for the dissociation constant (KD), rather than draw an absolute conclusion of ‘no binding’. But even an accurate lower limit often requires additional experiments, because the absence of observed binding—say in a gel shift, filter binding, or pull-down experiment—can arise either because there is no significant binding or because the complex does not withstand the assay conditions. While this objection may seem like a technicality, there are many instances where known binders do not give a gel shift or filter binding.

Immuno-precipitation and pull-down assays are pervasive in current biological investigations and are often interpreted in terms of ‘binding’ or ‘no binding’. But the reality of the interpretation of these experiments—and the reality of molecular interactions—is more nuanced. A ligand with the same affinity, slightly lower affinity, or even higher affinity than another ligand with demonstrated binding can incorrectly be concluded to ‘not bind’.

Consider, for example, an RNA pull-down with an RNA binding protein with KD = 10−9 M and kon = 108 M−1 s−1; this gives koff = 0.1 s−1 or a half-life for dissociation of ~10 s. If the washing steps following a pull-down take 30 s, only ~10% of the complex is expected to remain. If the affinity is 10-fold weaker (koff = 1 s−1), then no detectable complex is likely to remain after 30 s of washing (10−13 of the starting amount). Further, if another RNA ligand binds with the same affinity, but 10-fold slower (and thus also dissociating 10-fold slower; koff = 0.01 s−1, half-life of ~100 s), most (~75%) of the complex will remain after the 30 s washing steps despite an identical KD to the first ligand. In addition, the limited dynamic range of visual readouts of gels that are often used to evaluate pull-down experiments increases the danger of misinterpretation or overinterpretation of these experiments.

Overall, observing binding in pull-downs and related experiments is a complex function of the experimental components and conditions. This doesn’t at all mean these experiments should not be done—they often provide critical clues and insights into biology. But, for these and all experiments, we need to keep in mind the nature of the assay, and thus what can and cannot be concluded from the experiment.

Whether binding is absent or not detected can be tested by using approaches that directly report on the equilibrium between bound and unbound components in solution (e.g. ITC, fluorescence anisotropy, and other fluorescence-based techniques), as opposed to indirect approaches like native gel shift and pull-downs that are based on physically separating bound and unbound components, so that unstable complexes may fall apart prior to the detection step. Nevertheless, direct approaches also have limitations. For example, fluorescence intensity or FRET (Förster resonance energy transfer) is limited at high concentrations by inner filter effects, and ITC will miss binding events when the release (or uptake) of heat upon binding is too small (i.e. the binding enthalpy is too small).

A simple way to test whether binding occurs when there is no binding signal is to carry out a competition experiment. If the ligand is bound but not detected in an approach such as native gel shift or filter binding, it will still lessen binding of another ligand for which there is an established signal. The amount lessened depends quantitatively on the KD values and concentrations of each ligand, given sufficient time for equilibration. A competition experiment to obtain the KD value for a weak RNA substrate of Puf4 is shown in Appendix 3, along with the binding scheme and equation to determine the KD value.

Competition binding measurements can also have a practical benefit; after an initial KD is determined for a labeled substrate, KD values for additional substrates can be determined by competition without labeling each substrate.

Discussion

Given the increasingly multi-disciplinary nature of research, scientists are increasingly venturing into disciplines outside their expertise. Our goal is to support these valuable efforts by enabling both experts and non-experts in thermodynamics to get the most out of their binding experiments, and to help them evaluate work by others, published or under review for publication.

While the number of steps described to obtain reliable equilibrium data may initially seem daunting, the accompanying experimental illustrations and guides can transform an opaque process into one that is readily understandable and can be carried out in a straightforward, stepwise fashion by researchers from varied backgrounds.

We found it useful to develop and use an Equilibrium Binding Checklist to organize our approach and findings. We provide a template of such a checklist, along with completed examples in Appendix 4 (Appendix 4—figure 1, 2, 3). We expect that many readers will find these valuable.

There has been much discussion about problems with reproducibility and rigor in the scientific literature. Historically, a powerful means to ensure reliability of published data has been to develop community standards. Reporting guidelines have been successfully adopted by journals in a variety of fields, including structural biology, enzymology (http://www.beilstein-institut.de/en/projects/strenda/guidelines), organic synthesis (e.g. http://pubs.acs.org/page/joceah/submission/ccc.html), and many others, and new standards, guidelines and databases are continually being devised (see https://fairsharing.org/ for a curated list). We encourage journals to adopt analogous standards for reporting binding measurements. Contingent on implementation of such standards, we ultimately envision a well-curated and well-documented quantitative database that is routinely used to build and test models for individual molecular interactions and for cellular and molecular networks.

Survey of published equilibrium binding measurements

We surveyed 100 papers, including 66 papers from the list of quantitative RNA/protein studies assembled by the Liu lab and 34 additional studies reporting KD and apparent KD values for RNA/protein interactions (Supplementary file 1). To confirm that our survey was not biased, we also scored 20 publications from a single PubMed search for ‘RNA protein binding dissociation constant’, after confirming that they reported KD values for RNA/protein binding. Four of the 20 papers also appeared in the above list. The fractions of papers controlling for equilibration and/or titration were similar to those in the main survey (Figure 1): 30% of the 20 papers controlled both for equilibration and titration, 15% controlled for neither, 50% only controlled for titration and 5% only controlled for equilibration.

Equilibration was evaluated as follows. If a study reported systematically varying the incubation time, it was counted as controlled for equilibration. If dissociation kinetics were measured in addition to performing equilibrium measurements (n = 3), the study was scored as equilibration-controlled, but only if the reported incubation time was at least three half-lives based on the reported koff, and only if the kinetic and equilibrium experiments were performed at the same conditions (n = 1). Studies exclusively using approaches that intrinsically monitor the binding progress (ITC, SPR, biolayer interferometry [BLI]) also were counted as equilibration controlled. However, if several approaches were used in a given study to determine affinities for distinct binding interactions and/or conditions, and if for at least one approach time was not varied, the study was scored as not equilibration controlled. Some exceptions where equilibration can be reasonably assumed are noted in Supplementary file 1.

To generate Figure 1—figure supplement 1, we used the incubation times reported for non-equilibration controlled binding experiments. If a narrow range of times (e.g. 15–20 min, 45–60 min; n = 2) was indicated, this was not counted as systematically varying time and the longer time was used for Figure 1—figure supplement 1. If only a lower limit of the incubation time was reported (e.g. ‘at least 30 min’; n = 1), this lower limit was used for Figure 1—figure supplement 1. If two sequential incubations were performed at different temperatures (e.g. ‘10 min at room temperature and 10 min at 4°C’, n = 4), the total incubation time was used for the purposes of the survey. However, since affinity is condition-specific, only equilibration at a constant temperature can yield meaningful KD values, and two-temperature incubations should be avoided.

To evaluate if titration was controlled for, first, we confirmed if the concentration of the limiting species was systematically varied to determine effects on KD (n = 5); these studies were counted as titration controlled. If a study reported a range of concentrations of the limiting species, without stating that the effects on KD were assessed, we did not count this as a titration control, as in practice such a range typically only indicates optimization of radioactive/fluorescent signal to account for radioactive decay and/or varying labeling efficiencies. For the remaining studies, we asked if Equation 4b (which assumes the binding regime) or Equation 5 (which also allows for the intermediate regime) was used to fit the data. If no equation was indicated, or if the midpoint of the binding curve/gel signal was used to determine the KD, or if linear transformation was used in lieu of the hyperbolic fit, we counted the study as using Equation 4b. For studies using Equation 4b, we asked if the lowest apparent KD value was in at least 10-fold excess over the limiting component concentration, in which case we counted the study as titration controlled. If a range of limiting component concentrations was reported, we used the lowest value. If only the amount (not concentration) of the limiting species was reported, the concentration was calculated based on the provided volume or, if not indicated, based on a 10 µL reaction volume; nevertheless, binding equilibria depend on concentrations, not amounts, and concentrations, in units of ‘M’, should always be indicated. If Equation 5 was used (incl. all ITC measurements), we counted the study as titration controlled, unless the reported KD was more than 1000-fold below the limiting species concentration (corresponding to a cutoff typically used in ITC). For simplicity, we assumed that all SPR/BLI measurements (where the concentration of the immobilized species is difficult to estimate and not reported) were titration controlled; nevertheless, we emphasize the importance of explicitly reporting controls for mass transport in SPR measurements. If multiple approaches were used, but at least in one approach titration was not controlled for according to the above criteria, the study was scored as not titration controlled, unless the affected values were corroborated by a titration-controlled approach in the same study.

If no details on the incubation time and/or the concentration of the limiting reagent were provided, but instead a previous study was cited (‘as described’, n = 4), the information for the above evaluation was obtained from the cited study. This included two cases in which the authors had performed rigorous equilibration and titration controls in their previous referenced work.

Puf4 purification

The RNA-binding domain (residues 537–888) of S. cerevisiae Puf4 was cloned into a custom pET28a-based expression vector in frame with an N-terminal 6X His-tag and a C-terminal SNAP tag (New England Biolabs, Ipswich, MA). The construct was transformed into E. coli protein expression strain BL21 (DE3) and protein expression was induced at an OD600 of 0.6 with 1 mM IPTG at 20°C for ~20 hr. Induced cells were harvested by centrifugation at 4500 × g for 20 min. Cell pellets were re-suspended in Buffer A (20 mM HEPES-sodium (HEPES-Na)), pH 7.4, 500 mM potassium acetate (KOAc), 5% glycerol, 0.2% Tween-20, 10 mM imidazole, 2 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF) and cOmplete, Mini, protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) and lysed four times using an Emulsiflex (Avestin, Inc, Ottawa, ON, Canada). The lysate was clarified by centrifugation at 20,000 × g for 20 min, nucleic acids were precipitated with polyethylene imine (0.21% final concentration) at 4°C for 30 min with constant stirring and pelleted by centrifugation at 20,000 × g for 20 min. The supernatant was loaded on a Nickel-chelating HisTrap HP column (GE Healthcare, Pittsburgh, PA). Bound protein was washed extensively over a shallow 10–25 mM imidazole gradient and eluted over a linear 25–500 mM gradient of imidazole. Peak Puf4 protein fractions were pooled and desalted into Buffer B (20 mM HEPES-Na, pH 7.4, 50 mM KOAc, 5% glycerol, 0.1% Tween-20, 2 mM DTT) using a desalting column. The His-tag was cleaved by overnight incubation with His-tagged TEV protease at 4°C, and the protein was purified on a HisTrap HP column. The flow-through was desalted into Buffer B and loaded on a HiTrap Q HP column (GE Healthcare) and washed extensively with Buffer B to remove any bound RNA. Protein was eluted over a linear gradient of potassium acetate from 50 to 1000 mM. Protein fractions were pooled and desalted into Buffer C (20 mM HEPES-Na, pH 7.4, 100 mM KOAc, 5% glycerol, 0.1% Tween-20 and 2 mM DTT), concentrated and diluted two-fold with Buffer C containing 80% glycerol for final storage at −20°C. UV absorbance spectra indicated that the protein was free from significant RNA contamination (<1 RNA base per protein).

RNA 5´-end labeling

Puf4_HO RNA (AUGUGUAUAUUAGU; Integrated DNA Technologies (IDT), Coralville, IA; 5 µM) was labeled with equimolar [γ-32P] ATP (Perkin Elmer, Inc, Boston, MA) using T4 polynucleotide kinase (Thermo Fisher Scientific, Vilnius, Lithuania) and purified by non-denaturing gel electrophoresis (20% acrylamide). The RNA was eluted into TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) at 4°C overnight, and the lower limit of eluted RNA concentration, assuming no unlabeled RNA, was determined by scintillation counting and calibration against the specific activity of the [γ-32P] ATP stock used for labeling. The upper limit of RNA concentration was calculated from total RNA input and the elution buffer volume, assuming a 100% yield.

Equilibrium binding measurements

All reactions were performed in a binding buffer containing 20 mM HEPES-sodium or HEPES-potassium buffer, pH 7.4, 2 mM magnesium chloride (MgCl2), 100 mM KOAc, 2 mM DTT, 0.2% Tween 20, 5% glycerol, 0.1 mg/ml BSA, at 25 or 0°C, as indicated. The protein and labeled RNA dilutions were prepared in binding buffer at two-times the indicated concentration and were kept on ice until the binding reactions were initiated by mixing 10 µL of protein with 10 µL of labeled RNA. The pipette tips used for mixing and aliquoting the 0°C reactions were kept on ice. The labeled RNA concentrations and incubation times are indicated in the individual figure legends. Following the incubation, 7.5 µL aliquots were moved to 5 µL of ice-cold loading buffer containing 6.25% Ficoll PM 400 (Sigma-Aldrich, Saint Louis, MO), 0.075% bromophenol blue (BPB), and 2.5 µM unlabeled Puf4_HO RNA. The unlabeled RNA in the loading buffer prevented additional association to the labeled RNA from occurring during sample loading (Appendix 2—note 2). Control experiments indicated negligible re-equilibration in loading buffer (t1/2 ≥ 3 hr in three independent measurements), consistent with the slow dissociation rate constant measured in binding buffer at 0°C (Appendix 1). All samples were loaded on the gel within 20 min from mixing with the loading buffer. Non-denaturing acrylamide gels (20%) were pre-run for at least 1 hr at 42 V/cm constant voltage, 4–6°C with 0.5x TBE buffer (50 mM Tris, 42 mM boric acid, 0.5 mM EDTA•Na2, pH 8.5–8.6 final) using a circulating cooling system. Aliquots (7.5 µL) were carefully loaded on continuously running gels and separated for 45–90 min. (Extreme caution must be exercised at this step; see, e.g. https://ehs.stanford.edu/reference/electrophoresis-safety for electrical safety hazards.) The gels were dried and exposed to phosphorimager screens, scanned with a Typhoon 9400 Imager and quantified with TotalLab Quant software (TotalLab, Newcastle-Upon-Tyne, UK). Fitting was performed with KaleidaGraph 4.1 (Synergy Software, Reading, PA; RRID:SCR_014980).

The KD values in Table 2 indicate the average and standard error from five independent equilibrium experiments (25°C). For 0°C measurements, KD(hyperbolic) indicates the upper limit determined using Equation 4b at the lowest RNA concentration (Figure 6C,D); KD(quadratic) indicates the average and standard error of KD values determined with Equation 5 at the four RNA concentrations shown in Figure 6C,D.

Kinetic measurements

Measurements of koff (Appendix 1) were performed by incubating the indicated concentrations of Puf4 with trace concentration of labeled Puf4_HO RNA for 10 min at 25°C or 0°C in the binding buffer described in Equilibrium binding measurements. Labeled RNA concentrations were 0.04–0.5 nM, corresponding to the lower and upper limits, as defined in RNA 5´-end labeling. Dissociation was initiated by transferring the binding reaction to 2.5x volume of unlabeled chase in binding buffer. The chase RNA concentrations in the final reaction were 250 nM and 1000 nM. At various times, 7.5 µL aliquots were moved to 5 µL of ice-cold loading buffer containing 6.25% Ficoll PM 400% and 0.075% BPB, and 7.5 µL aliquots were loaded on a pre-run, continuously running 20% non-denaturing gel at 4–6°C. All pipette tip boxes and solutions used for the 0°C reactions were kept on ice. The chase solution for the 25°C reaction was pre-warmed in a 25°C water bath for 10 min before initiating the dissociation reaction. All time courses were fit to single exponentials using KaleidaGraph 4.1.

The effectiveness of unlabeled Puf4_HO RNA chase was tested by pre-incubating 10 nM Puf4 with 100–1000 nM unlabeled RNA (final concentrations) for 12 min at 25°C before adding trace amount of labeled Puf4_HO RNA (0.04–0.4 nM). The fractions of bound labeled RNA ranged from 0.01 (1000 nM) to 0.1 (100 nM), compared to 0.95 fraction bound in the absence of chase, confirming the effectiveness of the chase.

The koff values reported in Table 2 indicate the average and standard error from two replicate experiments (25°C) or the average and standard error across different concentrations in a single experiment (0°C).

Values of kon were determined by mixing 40 µL each of trace labeled RNA solution (0.004–0.05 nM) and varying dilutions of Puf4. At varying times, 7.5 µL aliquots were transferred to 5 µL of ice-cold loading buffer containing 6.25% Ficoll PM 400, 0.075% BPB, and 2.5 µM unlabeled Puf4_HO RNA and loaded on a 20% gel as above. The protein and RNA solutions were pre-incubated at the reaction temperature (0°C or 25°C) before mixing, and ice-cold tips were used for the 0°C reactions. To control for titration by labeled RNA at the low protein concentrations used, at 0°C, the equilibration rate constants were also measured at three-fold higher labeled RNA concentration, giving consistent rate constants within 1.1–1.3-fold (Appendix 1).

The kon values reported in Table 2 are the slopes and standard errors of linear fits to observed rate constants from two replicate experiments (25°C) or a single experiment (0°C). The kon values were corrected for the active protein fraction.

Measuring the fraction of active protein by titration

Unlabeled Puf4_HO RNA (10 or 100 nM) was incubated for 30 min with varying Puf4 concentrations in the presence of trace labeled Puf4_HO RNA (0.06–0.4 nM); the labeled and unlabeled RNA was pre-mixed before adding Puf4. The fraction bound RNA was determined as described in Equilibrium binding measurements.

Competition measurements

Trace labeled Puf4_HO RNA (0.02–0.19 nM) was equilibrated with 0.4 nM or 1.2 nM Puf4 and diluted two-fold into solutions containing varying concentrations of unlabeled competitor RNA (CGUAUAUUA; IDT). The reactions were incubated at 25°C for the indicated time, followed by transfer of 7.5 µL aliquots to 5 µL ice-cold loading buffer (6.25% Ficoll PM 400, 0.075% BPB, and 2.5 µM unlabeled Puf4_HO RNA). The samples were loaded immediately on a continuously running native acrylamide gel (4–5°C). The curves were fit to Equation 9, as described in Appendix 3.

Simulations

The simulated data in Figure 5 were generated by using Equation 4b (panel A) and Equation 5 (panel B) to calculate the fraction of bound RNA at each total protein concentration. In Figure 5—figure supplements 1, 2, 4 and 5, Equation 5 was used to calculate fractions bound at each protein and ligand concentration. In Figure 4—figure supplement 1, Equation 4b was used to determine the fraction of ligand bound at each protein concentration at equilibrium, assuming [P] = [P]total. This equilibrium value was then used as an amplitude (A) term in the single-exponential equation shown in Figure 2 to determine the fraction of bound ligand at each time point t: Fraction bound(t) = =.

The simulated data in Figure 5—figure supplement 3 were generated as follows. First, Equation 5 was used to calculate the expected fraction of bound RNA at equilibrium for each [R]total and [P]total indicated in the figure. Two-fold serial dilution of protein was chosen as representative of a typical equilibrium binding experiment. In the case of 0.001 nM Rtotal, Equation 4b was used instead to calculate the expected fraction bound, as this condition satisfies the [P]free = [P]total assumption. Random noise in fraction bound was then generated around each predicted data point by sampling from a normal distribution with the indicated standard deviation, using the scipy and random packages in Python. Ten binding series were generated this way for each condition and each noise level. These datasets were then individually fit to Equation 5 (or Equation 4b in the case of 0.001 nM Rtotal) in Prism 8 (GraphPad Software, LLC, San Diego, CA; RRID:SCR_002798), with the equations modified to include amplitude (A) and y axis offset (O) terms:

To facilitate fitting to Equation 6, [R]total was constrained to the known value, and the KD was constrained to positive values only, with the real affinity (0.1 nM) used as an initial estimate.

References 63

  1. 1.

    Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, Shmakov S, Makarova KS, Semenova E, Minakhin L, Severinov K, Regev A, Lander ES, Koonin EV, Zhang F. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353:aaf5573.

    Not in our library10.1126/science.aaf5573

  2. 2.
  3. 3.

    Altschuler SE, Lewis KA, Wuttke DS. Practical strategies for the evaluation of high-affinity protein/nucleic acid interactions. Journal of Nucleic Acids Investigation. 2013;4:3-28.

    Not in our library10.4081/jnai.2013.4646

  4. 4.

    Beloglazova N, Kuznedelov K, Flick R, Datsenko KA, Brown G, Popovic A, Lemak S, Semenova E, Severinov K, Yakunin AF. CRISPR RNA binding and DNA target recognition by purified cascade complexes from Escherichia coli. Nucleic Acids Research. 2015;43:530-543.

    Not in our library10.1093/nar/gku1285

  5. 5.

    Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Research. 2000;28:235-242.

    Not in our library10.1093/nar/28.1.235

  6. 6.

    Bevilacqua PC, Kierzek R, Johnson KA, Turner DH. Dynamics of ribozyme binding of substrate revealed by fluorescence-detected stopped-flow methods. Science. 1992;258:1355-1358.

    Not in our library10.1126/science.1455230

  7. 7.

    Boyle EA, Andreasson JOL, Chircus LM, Sternberg SH, Wu MJ, Guegler CK, Doudna JA, Greenleaf WJ. High-throughput biochemical profiling reveals sequence determinants of dCas9 off-target binding and unbinding. PNAS. 2017;114:5461-5466.

    Not in our library10.1073/pnas.1700557114

  8. 8.

    Buenrostro JD, Araya CL, Chircus LM, Layton CJ, Chang HY, Snyder MP, Greenleaf WJ. Quantitative analysis of RNA-protein interactions on a massively parallel array reveals biophysical and evolutionary landscapes. Nature Biotechnology. 2014;32:562-568.

    Not in our library10.1038/nbt.2880

  9. 9.

    Campbell ZT, Bhimsaria D, Valley CT, Rodriguez-Martinez JA, Menichelli E, Williamson JR, Ansari AZ, Wickens M. Cooperativity in RNA-protein interactions: global analysis of RNA binding specificity. Cell Reports. 2012;1:570-581.

    Not in our library10.1016/j.celrep.2012.04.003

  10. 10.

    Eftink MR. Fluorescence methods for studying equilibrium macromolecule-ligand interactions. Methods in Enzymology. 1997;278:221-257.

    Not in our library10.1016/s0076-6879(97)78013-3

  11. 11.
  12. 12.

    Greenfeld M, Solomatin SV, Herschlag D. Removal of covalent heterogeneity reveals simple folding behavior for P4-P6 RNA. Journal of Biological Chemistry. 2011;286:19872-19879.

    Not in our library10.1074/jbc.m111.235465

  13. 13.

    Hadizadeh N, Johnson RC, Marko JF. Facilitated dissociation of a nucleoid protein from the bacterial chromosome. Journal of Bacteriology. 2016;198:1735-1742.

    Not in our library10.1128/jb.00225-16

  14. 14.

    Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nature Protocols. 2007;2:1849-1861.

    Not in our library10.1038/nprot.2007.249

  15. 15.

    Herschlag D. RNA chaperones and the RNA folding problem. Journal of Biological Chemistry. 1995;270:20871-20874.

    Not in our library10.1074/jbc.270.36.20871

  16. 16.

    Hertel KJ, Herschlag D, Uhlenbeck OC. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry. 1994;33:3374-3385.

    Not in our library10.1021/bi00177a031

  17. 17.

    Hulme EC, Trevethick MA. Ligand binding assays at equilibrium: validation and interpretation. British Journal of Pharmacology. 2010;161:1219-1237.

    Not in our library10.1111/j.1476-5381.2009.00604.x

  18. 18.

    Jain N, Lin HC, Morgan CE, Harris ME, Tolbert BS. Rules of RNA specificity of hnRNP A1 revealed by global and quantitative analysis of its affinity distribution. PNAS. 2017;114:2206-2211.

    Not in our library10.1073/pnas.1616371114

  19. 19.

    James LC, Tawfik DS. Structure and kinetics of a transient antibody binding intermediate reveal a kinetic discrimination mechanism in antigen recognition. PNAS. 2005;102:12730-12735.

    Not in our library10.1073/pnas.0500909102

  20. 20.

    Jiang F, Zhou K, Ma L, Gressel S, Doudna JA. A Cas9-guide RNA complex preorganized for target DNA recognition. Science. 2015;348:1477-1481.

    Not in our library10.1126/science.aab1452

  21. 21.

    Karbstein K, Herschlag D. Extraordinarily slow binding of guanosine to the Tetrahymena group I ribozyme: implications for RNA preorganization and function. PNAS. 2003;100:2300-2305.

    Not in our library10.1073/pnas.252749799

  22. 22.

    Kladwang W, Hum J, Das R. Ultraviolet shadowing of RNA can cause significant chemical damage in seconds. Scientific Reports. 2012;2:517.

    Not in our library10.1038/srep00517

  23. 23.

    Koroshetz WJ, Behrman S, Brame CJ, Branchaw JL, Brown EN, Clark EA, Dockterman D, Elm JJ, Gay PL, Green KM, Hsi S, Kaplitt MG, Kolber BJ, Kolodkin AL, Lipscombe D, MacLeod MR, McKinney CC, Munafò MR, Oakley B, Olimpo JT, Percie du Sert N, Raman IM, Riley C, Shelton AL, Uzzo SM, Crawford DC, Silberberg SD. Framework for advancing rigorous research. eLife. 2020;9:e55915.

    Not in our library10.7554/elife.55915

  24. 24.

    Lambert N, Robertson A, Jangi M, McGeary S, Sharp PA, Burge CB. RNA Bind-n-Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins. Molecular Cell. 2014;54:887-900.

    Not in our library10.1016/j.molcel.2014.04.016

  25. 25.

    Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187-191.

    Not in our library10.1038/nature11556

  26. 26.

    LeCuyer KA, Crothers DM. Kinetics of an RNA conformational switch. PNAS. 1994;91:3373-3377.

    Not in our library10.1073/pnas.91.8.3373

  27. 27.

    Lin SY, Riggs AD. Lac repressor binding to non-operator DNA: detailed studies and a comparison of eequilibrium and rate competition methods. Journal of Molecular Biology. 1972;72:671-690.

    Not in our library10.1016/0022-2836(72)90184-2

  28. 28.

    Ma E, Harrington LB, O'Connell MR, Zhou K, Doudna JA. Single-Stranded DNA cleavage by divergent CRISPR-Cas9 enzymes. Molecular Cell. 2015;60:398-407.

    Not in our library10.1016/j.molcel.2015.10.030

  29. 29.

    Maerkl SJ, Quake SR. A systems approach to measuring the binding energy landscapes of transcription factors. Science. 2007;315:233-237.

    Not in our library10.1126/science.1131007

  30. 30.

    McDonnell JM. Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition. Current Opinion in Chemical Biology. 2001;5:572-577.

    Not in our library10.1016/s1367-5931(00)00251-9

  31. 31.

    Miller MT, Higgin JJ, Hall TM. Basis of altered RNA-binding specificity by PUF proteins revealed by crystal structures of yeast Puf4p. Nature Structural & Molecular Biology. 2008;15:397-402.

    Not in our library10.1038/nsmb.1390

  32. 32.

    Mueller-Planitz F, Herschlag D. Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: a unifying kinetic and structural mechanism. The Journal of Biological Chemistry. 2008;283:17463-17476.

    Not in our library10.1074/jbc.m710014200

  33. 33.

    Myszka DG. Improving biosensor analysis. Journal of Molecular Recognition. 1999;12:279-284.

    Not in our library10.1002/(sici)1099-1352(199909/10)12:5<279::aid-jmr473>3.0.co;2-3

  34. 34.

    Nature. Announcement: Reducing our irreproducibility. Nature. 2013;496:398.

    Not in our library10.1038/496398a

  35. 35.
  36. 36.

    Nutiu R, Friedman RC, Luo S, Khrebtukova I, Silva D, Li R, Zhang L, Schroth GP, Burge CB. Direct measurement of DNA affinity landscapes on a high-throughput sequencing instrument. Nature Biotechnology. 2011;29:659-664.

    Not in our library10.1038/nbt.1882

  37. 37.

    O'Connell MR, Oakes BL, Sternberg SH, East-Seletsky A, Kaplan M, Doudna JA. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. 2014;516:263-266.

    Not in our library10.1038/nature13769

  38. 38.

    Peluso P, Herschlag D, Nock S, Freymann DM, Johnson AE, Walter P. Role of 4.5S RNA in assembly of the bacterial signal recognition particle with its receptor. Science. 2000;288:1640-1643.

    Not in our library10.1126/science.288.5471.1640

  39. 39.

    Pisareva VP, Pisarev AV, Hellen CU, Rodnina MV, Pestova TV. Kinetic analysis of interaction of eukaryotic release factor 3 with guanine nucleotides. Journal of Biological Chemistry. 2006;281:40224-40235.

    Not in our library10.1074/jbc.m607461200

  40. 40.

    Plant AL, Locascio LE, May WE, Gallagher PD. Improved reproducibility by assuring confidence in measurements in biomedical research. Nature Methods. 2014;11:895-898.

    Not in our library10.1038/nmeth.3076

All 63 references

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.